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Cardiomyopathy is a frequent cause of morbidity and mortality in patients carrying the A3243G transition in the mitochondrial DNA
(mtDNA) tRNALeu(UUR) gene, the most common heteroplasmic single mtDNA defect. We used phosphorus magnetic resonance
spectroscopy (31P-MRS) to look for evidence of an in vivo bioenergetics defect in patients carrying the A3243G mtDNA mutation with and
without echocardiographic signs of left ventricle hypertrophy (LVH). Eight patients, three with LVH, carrying the A3243G mtDNA mutation
and 10 healthy subjects underwent one-dimensional chemical shift imaging 31P-MRS. In the patients, mean cardiac phosphocreatine to
adenosine triphosphate ratio (PCr/ATP) (1.55F 0.58) was significantly reduced compared to the control group (2.34F 0.14; P < 0.001).
Cardiac PCr/ATP was within the normal range only in one case that showed normal echocardiography. Our results point to a central role of
bioenergetics deficit in the development of cardiac hypertrophy in patients with the A3243G mtDNA mutation. Impaired cardiac energy
metabolism in patients with normal echocardiography suggests that the enhancement of mitochondrial function may be beneficial not only to
patients with cardiac hypertrophy but also to those patients carrying the mutation in the absence of signs of cardiac hypertrophy and/or
dysfunction but with cardiac bioenergetics deficit.
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1. Introduction [3,5]. Despite the phenotypic variability, the A3243G mu-The A3243G transition in the mitochondrial DNA
(mtDNA) tRNALeu(UUR) gene, the most common hetero-
plasmic single mtDNA defect [1] and with a prevalence of 1
in 6000 individuals [2], is characterised by a considerable
variability in its clinical expression [3]. The first description
of the A3243G mutation in a patient with mitochondrial
encephalomyopathy with lactic acidosis and stroke-like
episodes (MELAS) [4] was followed by the findings that
it can also be associated with diabetes and deafness, external
ophthalmoplegia, skeletal myopathy and cardiomyopathy0005-2728/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbabio.2004.05.003
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E-mail address: raffaele.lodi@unibo.it (R. Lodi).tation is associated in most cases with a respiratory chain
complex I deficiency [6] and only in some patients with
multiple complex defects which may involve cytochrome c
oxidase [7].
Cardiomyopathy is a frequent cause of morbidity and
mortality in patients carrying the A3243G mtDNA mu-
tation and usually has a hypertrophic phenotype. Cardiac
involvement had been reported in 20–30% of patients
with the full blown MELAS syndrome present [8] but it
may be present in MELAS patients with partial pheno-
type [9] as well as in isolation [3,10]. A more recent
investigation of cardiac manifestations in a population-
based cohort of patients with the A3243G mtDNA
mutation has detected LVH in more than 50% of cases
[11].
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magnetic resonance spectroscopy (31P-MRS) which is a
noninvasive technique not requiring the use of radioactive
tracers. 31P-MRS enables the measurement of the ratio of
phosphocreatine to adenosine triphosphate (PCr/ATP),
which has been shown to be a good measure of the energetic
state of cardiac muscle [12,13].
Given the very high prevalence of the A3243G mtDNA
mutation [2], the understanding of the extent of cardiac
involvement in patients with the mutation is critical in order
to develop effective ways of preventing lethal cardiovascu-
lar events. In the present study, we used in vivo 31P-MRS to
assess cardiac bioenergetics in subjects with or without
cardiomyopathy harbouring the A3243G mutation.2. Materials and methods
2.1. Subjects
Eight subjects carrying the A3243G mutation (seven
females; age range 30–51 years; 37F 7 years, meanF
S.D.) and 10 healthy volunteers (eight females, age range
27–51; 34F 7) underwent cardiac 31P-MRS study. Patients’
clinical and molecular data are reported in Table 1. Cases 1
to 4 (three sisters, cases 1, 2 and 3, and a cousin, case 4)
were from family A that had a MELAS phenotype and a
strong history of a cardiomyopathy (Table 1). Only case 1
from family A was symptomatic. Subjects 5 to 8 were from
three families (B to D) with no history of cardiomyopathy.
Patients 5 and 6 were sisters from family B with diabetes
and deafness phenotype; case 7, from family C, presented a
MELAS phenotype while case 8 from family D showed aTable 1
Clinical and molecular data of the subjects harbouring the mtDNA A3243G
mutation
Case
no.
Age
(years)
Age at
onset
(years)
Sex Mutated
mtDNA in
skeletal
muscle (%)
Family
phenotype
Clinical
features
1/A 30 13 F 72 MELAS SS/Df/St/Ep/
My/LVH/LVF
2/A 26 – F 86 MELAS Asymptomatic
3/A 30 – F 73 MELAS Asymptomatic
4/A 33 – F 64 MELAS Asymptomatic
5/B 41 25 F 80 Diabetes and
deafness
Df/DM/St
6/B 39 34 F 32 Diabetes and
deafness
CD/IGT
7/C 33 – M 6 MELAS Exercise
intolerance
8/D 50 13 F 53 MELAS/
diabetes
SS/Df/St/Ep/DM
CD= celiac disease, DM= diabetes mellitus, Df = sensorineural deafness,
Ep = epilepsy, IGT= impaired glucose tolerance, LVF= left ventricular
failure, LVH= left ventricular hypertrophy, MELAS=mitochondrial ence-
phalomyopathy with lactic acidosis and stroke-like episodes; My=myop-
athy, SS = short stature, St = stroke-like episodes.MELAS/diabetes phenotype. Detection of levels of mutated
mtDNA was determined on muscle from quadriceps in all
subjects carrying the A3243G mtDNA mutation as previ-
ously described [3].
Informed consent was obtained from each patient and
normal volunteer, and studies were carried out with approv-
al of the Central Oxford and Newcastle Ethics Committees.
2.2. Echocardiography
Echocardiography was performed in all patients using a
SONOS 5500 (Hewlett-Packard, Bracknell, UK) and
images stored on videotape or optical disk for later analysis.
Left ventricular (LV) dimensions were obtained using M-
mode; ejection fraction (EF) was calculated from LV vol-
umes (derived using modified Simpson’s rule). Left ven-
tricular mass index (LVMi) was derived from the M-mode
measurements using the Wikstrand formula [14], which uses
a modification of the prolate ellipsoid geometrical assump-
tion of LV morphology, and adjusted for height^2.7, as
recommended by de Simone et al. [15].
2.3. Magnetic resonance spectroscopy
Cardiac 31P-MRS studies were performed in 2.0-T whole
body magnet (Oxford Magnet Technology, Oxon, UK)
interfaced to a Bruker Avance spectrometer (Bruker Medical
GmbH, Ettlingen, Germany) as previously reported [16].
Subjects were positioned prone on a custom-made patient
bed incorporating a gantry to allow a range of surface coils
to be located beneath the subjects’ chest without moving the
subject. Standard multislice spin-echo images (TR = heart
rate, TE = 25 ms, slice = 10 mm, five slices) were acquired
using a double rectangular surface coil placed around the
chest to confirm subject placement in the magnet and guide
spectral localisation. After shimming was performed (using
a 15 cm diameter circular 1H surface coil centred beneath
the heart) the coil system was exchanged for an 8-cm
diameter circular 31P surface coil. Cardiac spectra were
acquired using a one-dimensional chemical shift imaging
(1D CSI) sequence to encode signals with depth into the
chest (64 encode steps, 64-cm field of view, 12 averages per
encode) [17]. Spectral localisation was improved by using
pre-saturation bands positioned over the chest wall using the
proton images [18]. Cardiac signal was acquired from an 8-
cm thick slice (again guided by the proton images) and
phase-encoded to provide spectra from 1 cm thick coronal
slabs through the heart. All proton and phosphorus data
acquisition was cardiac gated from a pulse oximeter probe
placed on a finger. Saturation correction factors for PCr and
ATP were measured by obtaining 1D CSI spectra from
phosphate phantoms of known longitudinal relaxation time,
T1, at different repetition rates. The pulse angle at the
surface of the coil was similar for equivalent power levels
whether the load was a phantom or a human subject. T1s of
PCr and ATP were assumed to be 4.3 and 2.52 s, respec-
Fig. 1. 31P-MRS cardiac spectra from a normal subject, and from two
patients carrying the A3242G mtDNA mutation. The PCr peak (relative to
ATP) is low in both patients, being lower in case 3 that belongs to a
pedigree with strong history of cardiomyopathy. 2-3 DPG indicates 2-3
diphosphoglycerate, PCr phosphocreatine, and g, a and h the three
phosphate groups of ATP.
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images were used to determine the location of spectra in the
cardiac 1D CSI data set which arose from the myocardium.
Cardiac spectra were fitted using a purpose-written interac-
tive frequency domain fitting program similar to a method
recently described [19]. Time domain signals were simulat-
ed for PCr, the three peaks of ATP, PDE, and 2,3-DPG
incorporating prior knowledge of peak chemical shifts and j-
couplings. Each signal component was simulated allowing
for missing initial data points (due to the phase encoding
duration of the acquisition experiment). Signal amplitude
and exponential decay of each component were adjustable
and a Gaussian decay could also be applied to the entire
FID. The simulated FID was Fourier transformed and
compared with the actual spectrum and root mean square
residuals calculated as a measure of the fit. After fitting, the
ATP signal was corrected for blood contamination based on
the amplitude of the 2,3-DPG [16] and the final PCr/ATP
ratio was calculated.
2.4. Statistical analysis
Individual results were taken as abnormal when they fell
outside the normal range. Statistical significance, deter-
mined by Student’s unpaired t test, was taken as P < 0.05.
Linear regression analysis was used to calculate correlation
coefficients.3. Results
The results of the echocardiographic studies are pre-
sented in Table 2. Four out of eight patients showed normal
echocardiograms. Two patients (case 1/A and 8/D) had
evidence of LV hypertrophy with an increase in LVMi
and one patient (case 5/B) showed increased IVSd as the
only abnormality. Ejection fraction was normal in allTable 2
Echocardiographic data of the subjects harbouring the mtDNA A3243G
mutation
Case no. IVSd
(cm)
PWd
(cm)
LVes
(cm)
LVed
(cm)
LVMi
(g/m2.7)
EF
(%)
1/A 1.67 1.17 3.15 3.93 90.5 58
2/A 0.61 0.65 2.53 4.16 21.3 61
3/A 0.76 0.77 3.05 4.37 25.9 67
4/A 0.74 0.81 2.82 3.29 17.6 59
5/B 1.17 0.91 2.37 4.03 35.3 57
6/B 0.74 0.82 2.64 4.24 26.4 62
7/C 0.80 0.93 3.76 4.35 30.5 48
8/D 1.23 1.10 2.67 4.03 53.4 50
Upper limit < 1.10 < 1.10 < 3.7 < 5.2 Male: 51 50
of normal
value
Female: 48
IVSd and PWd = septal and posterior wall thickness in diastole; LVes and
LVed = end-systolic and end-diastolic left ventricular dimensions;
LVMi = left ventricular mass index; EF = ejection fraction.patients except patient 7/C where it was minimally reduced
(48%, lower normal limit 50%). None of the eight patients
had evidence of diastolic dysfunction.
Composite cardiac 31P-spectra were obtained by adding
two or three 1D CSI rows collected from the apex, part of
the septum and of the posterior wall as determined from the
image. Typical resulting spectra are presented in Fig. 1
showing that PCr peak relative to ATP is mildly reduced in
case 5/B (PCr/ATP, corrected for saturation and blood
contamination, = 1.87) compared to a control subjectFig. 2. Cardiac phosphocreatine (PCr) to ATP ratios in controls (n= 10) and
in subjects carrying the A3243G mtDNA mutation from pedigrees A, B, C
and D. The horizontal bar indicates the PCr/ATP mean value in the control
group. Closed circles represent patients with left ventricular hypertrophy
and numbers identify the patients.
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(PCr/ATP= 0.80). In the patients’ group mean cardiac PCr/
ATP (1.55F 0.58) was significantly reduced compared to
the control group (2.34F 0.14; P= 0.0007). Cardiac PCr/
ATP was within the normal range only in case 6/B who
showed normal echocardiography (Fig. 2). In the patients
carrying the A3243G mutation, cardiac PCr/ATP did not
correlate with any of the echocardiographic variables
reported in Table 2 (data not shown). Cardiac PCr/ATP in
the patients tended to be inversely proportional to the
percentage of mutated mtDNA in the skeletal muscle
(r = 0.68) though the correlation failed to reach statistical
significance (P= 0.06).4. Discussion
Concentric left ventricular hypertrophy (LVH) is the
most frequent and characteristic cardiac abnormality in
patients carrying the A3243G mtDNA [11,20]. However,
the pathophysiological mechanisms linking the A3243G
mtDNA mutation to LVH are still unknown. We found that
abnormal in vivo cardiac bioenergetics is present in patients
not only with echocardiographic signs of LVH and/or
cardiac dysfunction, but also in patients without LV thick-
ening and in the absence of any discernible deterioration in
contractile performance.
Cardiac PCr to ATP ratio was reduced by more than 30%
in the patients as a group, being within the normal range
only in one case with normal echocardiography. Phospho-
creatine is a central metabolite in the biochemical pathways
that supply high-energy phosphates for muscle contraction.
Through the creatine-kinase reaction, PCr is in equilibrium
with ADP [21]. Thus, assuming unchanged total creatine,
low PCr/ATP in our patients leads to an increase in [ADP]
which is the major driving force of mitochondrial ATP
synthesis and represents an increased stimulus for ATP
production in the presence of malfunctioning oxidative
phosphorylation. Consistently, previous 31P-MRS studies
have shown increased [ADP] in the skeletal muscle and
brain of patients with the A3243G mtDNA mutation
[22,23].
The reduction in PCr/ATP found in patients with no signs
of cardiac hypertrophy or dysfunction suggests that cardiac
energy metabolism deficit in these patients is a direct effect
of the A3243G mtDNA mutation and is not secondary to
impaired LV function or LVH per se. The results of the
present study parallel those of our recent 31P-MRS cardiac
investigation of patients with Friedreich ataxia (FRDA)
[24], an autosomal recessive disorder which is characterised
by mitochondrial iron accumulation [25,26], deficit of
oxidative phosphorylation [25–27] and, in most patients,
cardiac hypertrophy [28]. Phosphocreatine to ATP ratios
were significantly reduced not only in FRDA patients with
LVH but also in a group of 10 FRDA patients with normal
echocardiographic features. The finding of low cardiac PCr/ATP in FRDA and in patients with the MELAS mutation
with no signs of LVH suggests that the bioenergetic deficit,
which is known to stimulate myocyte hypertrophy [29], may
have a central role in the development of cardiac hypertro-
phy in these patients.
A combination of different factors may contribute to the
heterogeneity in cardiac PCr/ATP found in our group of
patients. This would include the actual cardiac level of
mutated mtDNA, the extent of cardiac LVH that can, at
least partially, compensate for the metabolic dysfunction,
and the influence of both mitochondrial and nuclear genes.
The link between energy metabolism deficit and LVH is
supported by the findings that knockout mice deficient in
the heart/muscle isoform of the adenine nucleotide trans-
locator develop cardiac hypertrophy with mitochondrial
proliferation [30]. Consistently, Blair et al. [31] have re-
cently shown that energy depletion is a central abnormality
in different forms of familial hypertrophic cardiomyopathy.
In FRDA patients the cardiac bioenergetic deficit and
LVH have been shown to be partially reversed by the
administration of CoenzymeQ10 plus vitamin E [32] and
idebenone [33], respectively. Both CoenzymeQ10 and ide-
benone, a short-chain quinine analogue, act as free-radical
scavengers and electron transporters in the mitochondrial
respiratory chain. Administration of CoenzymeQ10 showed
brain bioenergetic improvements in patients with mtDNA
mutations [22] and, in a single patient with mitochondrial
cardiomyopathy, idebenone administration resulted in reso-
lution of the heart failure [34].
The management of patients carrying the MELAS mu-
tation with LVH and of asymptomatic subjects with the
mutation and at risk of developing cardiomyopathy (i.e.
belonging to pedigrees with a prominent cardiac involve-
ment) still represents an unresolved clinical issue. The
results of the present study suggest that the enhancement
of mitochondrial function may be beneficial not only to
patients with LVH but also to those patients carrying the
mutation in the absence of signs of cardiac hypertrophy and/
or dysfunction but with cardiac bioenergetics deficit.References
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